Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosis.
Takashi YamamuraNatalia AshtamkerDavid LadkaniToshiyuki FukazawaHideki HouzenMasami TanakaToshiro MiuraVolker KnappertzPublished in: Clinical & experimental neuroimmunology (2017)
The present study confirmed the well-established safety, tolerability and efficacy profile of GA in Japanese MS patients.
Keyphrases
- multiple sclerosis
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- magnetic resonance imaging
- rheumatoid arthritis patients
- end stage renal disease
- ankylosing spondylitis
- white matter
- chronic kidney disease
- physical activity
- computed tomography
- juvenile idiopathic arthritis
- mass spectrometry
- peritoneal dialysis
- prognostic factors
- open label
- clinical trial
- randomized controlled trial
- patient reported
- magnetic resonance
- contrast enhanced
- placebo controlled